These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32071402)

  • 1. Advances in ocular drug delivery systems.
    Kang-Mieler JJ; Rudeen KM; Liu W; Mieler WF
    Eye (Lond); 2020 Aug; 34(8):1371-1379. PubMed ID: 32071402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in ocular drug delivery: emphasis on the posterior segment.
    Kang-Mieler JJ; Osswald CR; Mieler WF
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1647-60. PubMed ID: 24975820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema.
    Wong CW; Wong TT
    Br J Ophthalmol; 2019 Oct; 103(10):1356-1360. PubMed ID: 31040133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel drug delivery systems for retinal diseases. A review.
    Lee SS; Robinson MR
    Ophthalmic Res; 2009; 41(3):124-35. PubMed ID: 19321933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery methods for posterior segment disease.
    Hsu J
    Curr Opin Ophthalmol; 2007 May; 18(3):235-9. PubMed ID: 17435432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy.
    Yilmaz T; Cordero-Coma M; Lavaque AJ; Gallagher MJ; Padula WV
    Curr Pharm Biotechnol; 2011 Mar; 12(3):337-46. PubMed ID: 20939800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
    Ou WC; Brown DM; Payne JF; Wykoff CC
    Am J Ophthalmol; 2017 Aug; 180():8-17. PubMed ID: 28549848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal steroids for the treatment of retinal diseases.
    Sarao V; Veritti D; Boscia F; Lanzetta P
    ScientificWorldJournal; 2014; 2014():989501. PubMed ID: 24526927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
    Wecker T; Ehlken C; Bühler A; Lange C; Agostini H; Böhringer D; Stahl A
    Br J Ophthalmol; 2017 Mar; 101(3):353-359. PubMed ID: 27215744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of intravitreal dexamethasone implant (Ozurdex®) on retrobulbar hemodynamics in patients with diabetic macular edema and retinal vein occlusions.
    Gok M; Altas H; Kapti HB
    Cutan Ocul Toxicol; 2019 Sep; 38(3):240-248. PubMed ID: 30773934
    [No Abstract]   [Full Text] [Related]  

  • 12. Evolution of intravitreal therapy for retinal and macular disorders.
    Panos GD
    J Int Med Res; 2020 Jan; 48(1):300060518771411. PubMed ID: 29726284
    [No Abstract]   [Full Text] [Related]  

  • 13. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.
    Alshaikh RA; Waeber C; Ryan KB
    Adv Drug Deliv Rev; 2022 Aug; 187():114342. PubMed ID: 35569559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].
    Jonas JB; Kreissig I; Kamppeter B; Degenring RF
    Ophthalmologe; 2004 Feb; 101(2):113-20. PubMed ID: 14991306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases.
    Seah I; Zhao X; Lin Q; Liu Z; Su SZZ; Yuen YS; Hunziker W; Lingam G; Loh XJ; Su X
    Eye (Lond); 2020 Aug; 34(8):1341-1356. PubMed ID: 32001821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
    Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
    JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Rupenthal ID
    Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal pharmacotherapy: applications in retinal disease.
    Prasad AG; Schadlu R; Apte RS
    Compr Ophthalmol Update; 2007; 8(5):259-69. PubMed ID: 18201513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging therapies in the management of macular edema: a review.
    Sacconi R; Giuffrè C; Corbelli E; Borrelli E; Querques G; Bandello F
    F1000Res; 2019; 8():. PubMed ID: 31448093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular morbidity associated with intravitreal triamcinolone acetonide.
    Konstantopoulos A; Williams CP; Newsom RS; Luff AJ
    Eye (Lond); 2007 Mar; 21(3):317-20. PubMed ID: 16710433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.